A Multinational Real-World Study on the Clinical Characteristics of Patients with Type  2 Diabetes Initiating Dapagliflozin in Southern Europe

ConclusionsSignificant differences were seen among patients initiating dapagliflozin in southern Europe. Our results suggest that dapagliflozin was being initiated at different stages of the disease according to the country and prescribing settings. Such geographic heterogeneity may have an impact upon effectiveness of dapagliflozin on glucose lowering, as well as cardiovascular and renal outcomes.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research